Exchange Traded Concepts LLC Reduces Stock Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Exchange Traded Concepts LLC trimmed its position in Twist Bioscience Co. (NASDAQ:TWST) by 31.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,830 shares of the company’s stock after selling 6,311 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Twist Bioscience were worth $643,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new position in shares of Twist Bioscience during the 3rd quarter worth $34,000. Signaturefd LLC boosted its stake in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares during the period. Beaird Harris Wealth Management LLC acquired a new stake in shares of Twist Bioscience during the third quarter valued at about $95,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares during the period. Finally, Farther Finance Advisors LLC boosted its position in shares of Twist Bioscience by 1,173.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,401 shares of the company’s stock worth $154,000 after purchasing an additional 3,134 shares during the period.

Twist Bioscience Stock Down 4.5 %

TWST stock opened at $49.52 on Thursday. The business has a 50 day moving average price of $48.00 and a 200 day moving average price of $46.38. The stock has a market cap of $2.94 billion, a price-to-earnings ratio of -13.76 and a beta of 1.85. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90.

Insider Transactions at Twist Bioscience

In related news, insider Dennis Cho sold 659 shares of the firm’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $27,388.04. Following the transaction, the insider now owns 94,481 shares in the company, valued at $3,926,630.36. This trade represents a 0.69 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Paula Green sold 860 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $52.70, for a total value of $45,322.00. Following the completion of the sale, the senior vice president now owns 133,715 shares of the company’s stock, valued at approximately $7,046,780.50. This represents a 0.64 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 89,801 shares of company stock worth $4,147,858. 3.01% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

TWST has been the topic of a number of research reports. Barclays decreased their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. Robert W. Baird increased their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. Wolfe Research began coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. Leerink Partners increased their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Finally, TD Cowen reissued a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $51.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.